Free Trial

Organovo Q4 2024 Earnings Report

Organovo logo
$0.38 0.00 (-0.78%)
As of 01/21/2025 04:00 PM Eastern

Organovo EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.42
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.08 million
Beat/Miss
Missed by -$50.00 thousand
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Q4 2024
Time
N/A

Conference Call Resources

Organovo Earnings Headlines

Organovo (NASDAQ:ONVO) Research Coverage Started at StockNews.com
Organovo Appoints Norman Staskey As CFO
Kamala’s final humiliation
Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behind closed doors with some of America’s savviest investors. The obscure, little-known companies we believe could 5x, even 10x, under Trump’s second term…
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat